Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29452951 | 1.00 | GLA (0.42) | GLAHTTKDM4EGAAL3MBTL1 | |
| SCHEMBL11093101 | 0.89 | HTT (0.43) | GLAHTTKDM4EGAAL3MBTL1 | |
| SCHEMBL8144119 | 0.89 | HTT (0.47) | GLAHTTKDM4EGAAL3MBTL1 | |
| SCHEMBL4412358 | 0.84 | GLA (0.40) | GLAHTTKDM4EGAAL3MBTL1 | |
| SCHEMBL31257953 | 0.82 | GLA (0.39) | GLAHTTKDM4EGAAL3MBTL1 | |
| SCHEMBL21915027 | 0.82 | ALDH1A1 (0.42) | GLAHTTKDM4EGAAALDH1A1 | |
| SCHEMBL21915029 | 0.82 | GLA (0.39) | GLAHTTKDM4EGAAL3MBTL1 | |
| SCHEMBL4412381 | 0.80 | HTT (0.44) | GLAHTTKDM4EGAAL3MBTL1 | |
| SCHEMBL6872415 | 0.80 | GLA (0.41) | GLAHTTKDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL19436393 | 0.77 | GLA (0.37) | GLAHTTKDM4EGAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360146-A1 | BRUTON'S TYROSINE KINASE AND MUTANT DEGRADER, COMPOSITION AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2024-10-31 | — | — | US | disclosed |
| EP-4342892-A1 | BRUTON'S TYROSINE KINASE AND MUTANT DEGRADER, COMPOSITION AND APPLICATION THEREOF | Hangzhou Healzen Therapeutics Co., Ltd. (CN) | 2024-03-27 | — | — | EP | disclosed |
| CN-115557933-A | Bruton tyrosine kinase and mutant degradation agent, composition and application thereof | 杭州和正医药有限公司 | 2023-01-03 | — | — | CN | disclosed |
| CN-111423387-B | Preparation method of Giltertinib key intermediate | 苏州康纯医药科技有限公司 | 2022-03-08 | — | — | CN | disclosed |
| CN-111423387-B | Preparation method of Giltertinib key intermediate | 苏州康纯医药科技有限公司 | 2022-03-08 | — | — | CN | disclosed |
| CN-111423387-A | Preparation method of Giltertinib key intermediate | 苏州康纯医药科技有限公司 | 2020-07-17 | — | — | CN | disclosed |
| CN-111423387-A | Preparation method of Giltertinib key intermediate | 苏州康纯医药科技有限公司 | 2020-07-17 | — | — | CN | disclosed |
| US-9487491-B2 | Diamino heterocyclic carboxamide compound | ASTELLAS PHARMA INC. (JP) | 2016-11-08 | — | — | US | disclosed |
| US-9487491-B2 | Diamino heterocyclic carboxamide compound | ASTELLAS PHARMA INC. (JP) | 2016-11-08 | — | — | US | disclosed |
| EP-2428508-B9 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC (JP) | 2016-04-20 | — | — | EP | disclosed |
| EP-3009428-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2016-04-20 | — | — | EP | disclosed |
| EP-2428508-B1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC (JP) | 2015-12-16 | — | — | EP | disclosed |
| US-8969336-B2 | Diamino heterocyclic carboxamide compound | ASTELLAS PHARMA INC. (JP) | 2015-03-03 | — | — | US | disclosed |
| US-8969336-B2 | Diamino heterocyclic carboxamide compound | ASTELLAS PHARMA INC. (JP) | 2015-03-03 | — | — | US | disclosed |
| US-20140371196-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-12-18 | — | — | US | disclosed |
| US-20140371196-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-12-18 | — | — | US | disclosed |
| CN-102421761-B | Diamino heterocyclic carboxamide compound | ASTELLAS PHARMA INC | 2014-06-18 | — | — | CN | disclosed |
| EP-2428508-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2012-03-14 | — | — | EP | disclosed |
| US-20120040968-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | WATERS TECHNOLOGIES CORPORATION (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040968-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | WATERS TECHNOLOGIES CORPORATION (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371196-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | EML4, ALK, ERBB4 | GLA 4240/4885HTT 3739/4885KDM4E 39/4885 |
| US-20240360146-A1 | BRUTON'S TYROSINE KINASE AND MUTANT DEGRADER, COMPOSITION AND APPLICATION THEREOF | BTK, ZAP70, SYK | GLA 2717/4885HTT 4401/4885KDM4E 849/4885 |
| US-20120040968-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | EML4, ALK, ERBB4 | GLA 4240/4885HTT 3739/4885KDM4E 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.